Tianshili: the subsidiary transfers 0.3% shares of i-mab to Huatai capital
Financial Associated Press, Nov. 19 (Reuters) - Tianshili announced that its holding subsidiary Tianshili biology transferred 0.3% of its shares in i-mab to Huatai capital at a total transfer price of US $12 million. After this transfer, the company's shareholding in i-mab will be reduced to 5.64%.
This text is a result of machine translation.
Related companies：
In-depth
Briefing Jun 07, 2022 08:38 PM
· Technology
Maohua Shihua: purchased 69% of the equity of simvoda ocean with RMB 420million
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing May 17, 2022 02:30 PM
· Technology
Zhao Dachun, deputy general manager of China Mobile: ensure that more than one million 5g base stations are opened before the 20th CPC National Congress
Briefing Apr 24, 2022 01:06 PM
· Financials
Notice: the State Information Office held a briefing on the 25th to introduce the opinions on promoting the development of individual pensions
Briefing Feb 28, 2022 08:18 PM
Monetary Policy Department of the central bank: China has the ability and conditions to effectively respond to external shocks and domestic downward pressure
See more
Read next
Insight
In-depth
Insight
In-depth